ESTABLISHMENT LABS HOLDINGS INC. financial statements
Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data ESTABLISHMENT LABS HOLDINGS INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
34.7
61.2
89.6
84.7
127
162
165
166
211
Cost of revenue
17
25.1
34.7
32.2
41.3
55.1
58.2
56.5
64.8
Gross profit
17.7
36.1
54.9
52.5
85.4
107
107
110
146
Research and development
6.86
12.7
15
13.8
18.3
20.3
26.4
19.7
20.2
Selling, general and administrative
30.8
47.3
70.8
66.6
92.2
126
146
140
165
Operating expenses
37.7
60
85.8
80.4
111
146
172
160
185
Operating income
-20
-23.9
-30.9
-27.9
-25.1
-39.7
-65
-50
-39
Interest expense
10.4
8.81
8.7
9.37
9.06
11.8
15.4
20.8
25.3
Interest income
0.02
0.02
0
0.02
0.02
0.09
1.02
1.48
0.42
Other non-operating income
-0.4
-2.39
-1.21
-2.68
-6.27
-3.18
0.82
-15.3
5.82
Pre-tax income
-34.8
-20.9
-37.5
-38
-39.7
-72.8
-78.6
-84.6
-58
Income tax
0.11
0.22
0.64
0.1
1.43
2.39
-0.08
-0.03
-6.96
Net income
-34.9
-21.1
-38.2
-38.1
-41.1
-75.2
-78.5
-84.6
-51.1
EBITDA
-22.6
-37.2
-62.2
-45.3
-32.8
EPS, basic
-3.41
-1.22
-1.86
-1.63
-1.72
-3.08
-3.07
-3.00
-1.72
EPS, diluted
-3.41
-1.22
-1.86
-1.63
-1.72
-3.08
-3.07
-3.00
-1.72
Shares, basic (weighted)
10.2
17.4
20.5
23.3
24
24.5
25.6
28.2
29.6
Shares, diluted (weighted)
10.2
17.4
20.5
23.3
24
24.5
25.6
28.2
29.6
Balance sheet
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
10.9
52.6
37.7
84.5
53.4
66.4
40
90.3
75.6
Receivables
13.1
17.6
22.8
19.1
24.4
35.4
46.9
65
77.5
Inventory
13.2
24.8
28.7
23.2
28.4
36.6
79.5
78.8
85.6
Other current assets
2.24
4.3
6.76
2.09
1.77
1.57
8.48
8.92
11.3
Total current assets
39.4
99.4
95.8
132
113
150
175
243
250
Property, plant and equipment
13.5
12.9
16.4
16.2
18.7
51.1
77.2
78
75.6
Lease right-of-use assets
2.61
2.21
3.7
3.38
5.56
4.34
Goodwill
0.47
0.47
0.47
0.47
0.47
0.47
0.47
1.21
1.21
Intangible assets
3.4
3.45
3.44
4.15
4.37
4.61
7.99
11.7
9.94
Other non-current assets
0.27
0.32
0.37
0.66
0.56
1.29
4.7
7.31
16.1
Total assets
57.1
117
117
156
140
211
269
347
357
Accounts payable
9.13
6.24
10.4
9.72
14.5
20
41.6
44.8
43.1
Accrued liabilities
2.33
6.13
10.7
14.5
16.2
17.2
13.7
16.5
18.9
Deferred revenue
0.91
0.91
0.79
1.21
0.77
1.69
1.84
1.75
1.21
Short-term debt
0
Total current liabilities
57.4
16.4
23.2
25.9
31.9
39
57.2
68.3
82.1
Long-term debt
48.1
49.8
51.9
175
189
220
248
Lease liabilities
1.92
1.9
3.2
2.71
4.2
2.82
Other non-current liabilities
4.67
3.55
2.46
2.33
2.39
1.63
1.65
1.68
1.14
Total liabilities
62.1
47.1
76.9
81.4
88.8
219
250
294
334
Total debt
48.1
49.8
51.9
175
189
0
248
Paid-in capital
28
15.2
21.2
26.7
36.6
49.9
63.7
77
87.6
Retained earnings
-67.9
-89
-127
-165
-206
-282
-360
-445
-496
Treasury stock
-6.47
-2.85
-2.85
-2.85
-2.85
-2.85
-2.85
-2.85
-2.85
Other comprehensive income
0.08
0.45
0.69
2.87
3.66
2.72
1.96
3.29
1.16
Shareholders' equity
-5.01
69.5
39.6
75
50.7
-8.19
18.4
53.1
23.5
Total equity
-5.01
69.5
39.6
75
50.7
-8.19
18.4
53.1
23.5
Total liabilities and equity
57.1
117
117
156
140
211
269
347
357
Shares outstanding
20.3
20.6
23.5
24.1
24.4
26.1
28.8
29.3
Cash flow statement
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-34.9
-21.1
-38.2
-38.1
-41.1
-75.2
-78.5
-84.6
-51.1
Depreciation and amortization
2.5
2.5
2.8
4.7
6.2
Stock-based compensation
7.32
6.53
5.72
10.4
13.4
14.4
14.4
11.4
Deferred income tax
0
0
0
-0.27
0.01
0.09
-3.71
-2.18
-9.44
Change in receivables
-6.91
-4.67
-5.51
3.81
-6.7
-12.3
-11.6
-26.3
-11.5
Change in inventory
-6.44
-6.98
-3.37
4.79
-7.64
-10.9
-42.2
-0.47
-7.06
Change in payables
-0.88
-3.91
1.83
-0.64
4.96
4.38
19
6.67
-2.3
Cash from operations
-32
-33.9
-30
-12.5
-27.5
-52.2
-88.5
-58.5
-50.9
Capital expenditures
-0.9
-1.73
-6.29
-2.11
-2.43
-2.85
-7.91
-6.11
-6.05
Acquisitions
0
0
-0.05
-0.31
Cash from investing
-0.85
-5.73
-7.77
-5.56
-7.16
-34.8
-24.5
-15.6
-7.03
Stock issued
0
0.64
0.71
63.9
0
0
84.5
99.5
0
Share buybacks
-4.51
0
Cash from financing
43
81.5
22.8
64.7
4.05
100
86.2
126
40.4
Exchange rate effect
0.21
-0.14
-0.02
0.27
-0.47
-0.36
0.51
-1.46
2.71
Net change in cash
10.4
41.8
-15
46.9
-31.1
12.9
-26.3
50.3
-14.8
Free cash flow
-32.9
-35.6
-36.3
-14.6
-30
-55
-96.4
-64.6
-56.9
Interest paid
2.86
5.38
5.95
6.96
6.93
5.36
5.69
9.81
20.5
Income taxes paid
0.15
0.14
0.65
0.32
0.65
2.13
2.17
1.74
0.42
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $65.97 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
70.5%
Gross profit / revenue.
Operating margin
-7.6%
Operating income / revenue.
Pre-tax margin
-19.3%
Pre-tax income / revenue.
Net margin
-15.8%
Net income / revenue.
FCF margin
-16.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-13.1%
Cash from operations / revenue.
Return on equity (ROE)
-180.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-11.1%
Net income / average total assets.
Return on invested capital (ROIC)
-7.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
8.3%
Research and development expense / revenue.
SG&A / revenue
69.9%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
4.9%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
3.7%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
27.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
9.3%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
20.0%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
33.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
11.1%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
22.7%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-55.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 5y
-20.7%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
3.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
19.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
18.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
5.2%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
6.6%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
4.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
3.84x
Current assets / current liabilities.
Quick ratio
2.27x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.10x
(Cash + short-term investments) / current liabilities.
Debt / equity
12.1x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
74.4%
Total debt / total assets.
Liabilities / assets
93.9%
Total liabilities / total assets.
Net debt
$190.5M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$1.29
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$8.16
Revenue / diluted weighted shares.
FCF per share
-$1.38
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.07
Cash from operations / diluted weighted shares.
Book value per share
$0.73
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
8.00x
Market cap / revenue.
P/B
91.0x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
179x
Market cap / tangible book value, when positive.
EV/Sales
8.77x
Enterprise value / revenue.
FCF yield
-2.1%
Free cash flow / market cap.
Earnings yield
-2.0%
Net income / market cap (the inverse of P/E).
What was ESTABLISHMENT LABS HOLDINGS INC.'s revenue in fiscal 2025?
ESTABLISHMENT LABS HOLDINGS INC. reported revenue of $211.1M for fiscal 2025, 27.1% higher than the year before.
Was ESTABLISHMENT LABS HOLDINGS INC. profitable in fiscal 2025?
No. It reported a net loss of $51.1M.
How much free cash flow did ESTABLISHMENT LABS HOLDINGS INC. generate in fiscal 2025?
Cash from operations of $50.9M minus capital expenditures of $6.0M left free cash flow of -$56.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.